Global Thyroid Gland Disorders Treatment Market 2019-2024 - Hyperthyroidism is Expected to Witness Rapid Growth -

DUBLIN--()--The "Thyroid Gland Disorders Treatment Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to's offering.

The market for thyroid gland disorders treatment is primarily driven by the increasing burden of the patient population with iodine deficiency. Added to that high alcohol and tobacco consumption is also leading to thyroid disorders in the developing regions which are driving factors for the market studied.

Key Market Trends

Hyperthyroidism is Expected to Witness Rapid Growth

Hyperthyroidism is a condition in which the thyroid gland produces thyroxin in excess amount. As per the National Institute of Health, an estimated prevalence of the disease is around 1-1.3% and it increases up to 4-5% in the older women. Also, the disease more commonly occurs in smokers.

Since smoking is increasing among the general population across the globe, there is an increasing number of people that are falling prey to the disease. Also, the awareness about hyperthyroidism is increasing in developing countries such as India which is ultimately driving the growth of the market studied. Furthermore, the easy availability of the antithyroid medications for hyperthyroidism is fueling the market.

North America is Believed to Dominate the Market

In North America, it is estimated that about 35 million people suffer from at least one form of thyroid disease. Several companies have collaborated with ATA (America Thyroid Association), where ATA has supported several research grants with about USD 2.2 million. In addition, multinational companies have frequently involved in raising awareness in American society through campaigns. For instance, Merck launched It's not you. It's your thyroid campaign in 2017 and 2018.

The annual awareness campaign is in collaboration with Thyroid Federation International (TFI), as it is observed by companies that the thyroid disorders are still poorly understood and often go underdiagnosed. The increased health infrastructure and high government involvement in the management of thyroid diseases make North America a major revenue contributor for the treatment of thyroid gland disorders treatment.

Competitive Landscape

The market for Thyroid Gland Disorder Treatment is moderately competitive and majorly consists of the global players. With the rising innovations in the therapeutics, it is believed that some small or mid-sized companies will be entering the market in the coming future.

Topics Covered





4.1 Market Overview

4.2 Market Drivers

4.2.1 Growing Patient Population with Iodine Deficiency

4.2.2 Rising Government Initiatives for Thyroid Gland Screening and Treatment

4.3 Market Restraints

4.3.1 Unfavourable Healthcare Reforms in Some Regions

4.3.2 Alternative Herbal and Acupuncture Therapies

4.4 Porter's Five Force Analysis


5.1 By Type of Disorder

5.1.1 Hypothyroidism

5.1.2 Hyperthyroidism

5.1.3 Others

5.2 By Route of Administration

5.2.1 Oral

5.2.2 Parenteral

5.2.3 Others

5.3 By Drug Class

5.3.1 Thioamides

5.3.2 Ionic inhibitors

5.3.3 Hormone Release Inhibitors

5.3.4 Others

5.4 By Distribution Channel

5.4.1 Wholesale Distribution

5.4.2 Retail Stores

5.4.3 Online Pharmacy

5.5 Geography

5.5.1 North America US Canada Mexico

5.5.2 Europe Germany UK France Italy Spain Rest of Europe

5.5.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.5.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa

5.5.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles

6.1.1 Abbvie Inc.

6.1.2 Amgen Inc.

6.1.3 GlaxoSmithKline PLC

6.1.4 Merck KGaA

6.1.5 Mylan N.V.

6.1.6 Novartis AG

6.1.7 Pfizer Inc.

6.1.8 Takeda Pharmaceutical Company Limited

6.1.9 Elexis Inc.

6.1.10 IBSA Pharma (IBSA Group)


For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs